Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Aiforia, Webcast, H2, 2025

By Inderes3/6/2026, 8:00 AM
Aiforia Technologies

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jukka Tapaninen
05:53 - 33:12

Good morning and welcome to Aiforia earnings announcement for 2025. My name is Jukka Tapaninen, Aiforia's CEO. Let's move forward. Today's agenda. I will give the highlights on H2 2025 and FY 2025, and some highlights on our strategy execution. And at the end of the session, we will have a Q&A. Let's get started. So last year. I've always said that we've been moving forward as planned on this journey we have. And after the IPO, when we decided to move to the clinical sector and focus on that side of the business. We've been building a really nice portfolio on the market. I will cover that a little bit later. But now we started to see traction on the revenue side as well. We've been focusing on building the portfolio, getting the first flagship customers in. And now the companies are moving to a more scale-up phase. Last year, we achieved 68% growth in clinical sector revenue. And for that number, we are very happy from Aiforia's side. And that growth was, of course, due to the fact that we have that interesting portfolio. We've been increasing new AI models so that we have more coverage. And at the same time. We've been introducing a lot of reselling partnerships and strategic partnerships. And Siemens Healthineers is one of those that we expect to be really, really important going forward. We have been moving forward in multiple fronts, increasing the portfolio, getting more traction in the market with the customers, and expanding the network. What we have, and as we are in a clinical business. The regulation is a really important part. And currently we have the biggest portfolio in the market. We covered a significant part of the clinical workflow. We got the IVDR certification last year. And introduced five AI models on that side. Currently, we have 11 CE-IVD marked solutions in our portfolio in 2025. Actually, one more, because in 2026, we got one additional one. But I will come back to that later. And at the same time. So we've been investing heavily on latest technologies. Meaning that we are speeding up our product development and those activities. But at the same time, all the different functions in a company. So we've been going through and seeing where we can use AI to increase the efficiencies and the profitability of the company. But, so it's multiple actions going on. But I will cover some of those in detail. This is our customer list. Some of these have already been introduced, for example, Mayo Clinic. It's a first clinical customer for us and has been there for multiple years, still going strong. So they have a Breast Cancer Suite in production already since 2023. So there's a lot of pathologists using the development platform. And we are innovating and developing new tools with Mayo Clinic. But I have to say, from the US market, we also got one of the world's leading cancer centers as a customer in Q4. But unfortunately, we are not allowed to tell the name of the customer. So that's why we made that nice release. And once we get the approval to release the name, we will do so. But I have to say that the US market is also moving forward. We did some changes in the organization last year so that it's more aligned with the strategy of the company. So we have the new pre-sales, sales, and delivery capabilities in the country, along with a healthy pipeline going forward. That's something that the US is definitely one of our key markets. For the other markets, we made significant progress last year. So we did. We got more deals from Italian markets. So we got the Lombardy Region, which is a really big one. It's 10.5 million people and 32 hospitals. And we started to deliver in Q4. So it's in an early phase of delivery, and we already booked some of the revenue out of that deal. But that's a really interesting and nice case. And same as France. The first big clinical customer for us was the Paris hospital region. And that is the biggest one in Europe. It's 38 hospitals in total. And we started to deliver that. We started to deliver with the prostate solution. And they are really happy. And it's in production in two hospitals now. And I just wanted to point out that even though we currently serve approximately 10 to 15 customers, our ambition is to expand to 50 clinical customers, a development that presents an opportunity to generate over half a million in recurring revenue. We are on that track, and Paris is a good example. So, out of the 38 hospitals, two are currently using one AI model, and we now have multiple AI models to deliver. Plus we have a lot of upsell to do in that particular customer. But the other thing about France I would also like to point out at this point in time is that we have been investing in the country. We built a full team. We put a legal entity in place and we have got a lot of traction. And there's also a lot of government support on accelerating AI in the country. And we are actually the only AI company that was chosen on those programs. Nantes is an interesting example of that, but we have also Institut Curie. It was a big win from a competition. And we expect that France will be in 2026 one of the big markets for us alongside Italy, the US, and the Nordic countries. But maybe one number, because everybody is always interested in numbers. Currently, this list generates a bit over 2 million in recurring revenue, and its full potential is estimated at seven to eight million. So when we get it at full speed, and keeping in mind that our ambition is to grow to, let's say, 50. Similar types of organizations and the other business, this is how we are going to start scaling up the business. On the investment side. As some might have noticed. We have a certain cost level and certain investment in place. So we have actually been reducing our overall investment level a bit. But we continue investing in development because that's the key. We are at the forefront of technology, deeply specialized in this area. We have been leading the game with our offerings. We need to ensure we maintain that position and address a couple of key points. So on the clinical side, we've obviously been using the latest technologies so that we can develop AI models quicker. The typical delivery time for an AI model was 18 months. Now we have these Vision Transformer technologies, Foundation Engines, and all the advantages from the latest technology. We think that we can reduce the development time from 18 months to eight months. A significant reduction on that. This allows for quicker monetization when we decide to build something and can commercialize it, recognizing it as revenue in our books. Customer deployment is another important aspect. Sometimes, some have questioned how long it will take us to deliver. But if we look at the current situation. We've been using the latest technologies to speed up those processes. And we can actually deliver in less than four weeks. Of course, there are certain prerequisites that have to be in place. The customer needs to have the scanners, they need to have the systems. But if you look at Aiforia's capabilities for delivering quickly, we can do that. So that's not blocking us on scaling up the business at all. Then, of course, as I said in the beginning, we've been focusing on using all of those AI tools for internal productivity, not only in product development but in all functions. Whether it's a hire to retire process or order to cash process or any of those core processes. We have already invested time, and we continue to do that so that we can actually leverage and do things quicker, better, higher quality, and so on. But the first major steps forward have been in R&D, improving product quality, connectivity to all surrounding systems, and the generalizability of products so that we can more easily replicate what we have built. But that's why. 6.6 million on investment on this side. I mentioned about the IVDR. So that's a big thing. It's one of those moats for getting into the clinical side of the business. And we are extremely happy. That we actually chose to be in a clinical market. The large volumes, bigger deals, continuing business on those customers, but also that it a little bit blocks the competition out. Because it's a regulatory approval process. Regardless of global circumstances, companies must comply with regulations so that they can sell in this market. And as I said before. We are leading the pack on this side. We have really nice offerings. I'll come back to that in a second. But last year, we got the IVDR, we got the first IVD-regulated products under that regulation. This year already introduced the Gastric Suite. And the whole point is that getting the IVDR is quite an effort, but once it's done, it's quicker to build new AI models and release them under that regulation. But we have done the heavy lifting, and now we need to monetize the investment we've made. I will come back to products a bit later, but as for the results from FY 2025 in brief: We grew 24%. And also, the growth was accelerating in H2 2025, and we are extremely happy that the clinical side of the business was picking up nicely. Clinical sector revenue grew 68% to 6.6 million, and EBIT and EBITDA both improved. So and that was according to our plan. We made some extraordinary investments last year on a strategy session revising our strategy. We incurred extra recruitment costs for leadership positions. Overall, we were on track with cost levels. And we were happy it was going down. The employee number was staying quite stable. And then we have a nice amount of cash at the end of the year. So we have a decent, decent runway in front of us. The majority of the business was coming from European key markets, with 12% from Finland and 20% from North America. And for 2026, I think that this pipeline will look more or less the same. Going forward. But the important thing, as I said. It's that we finally see the growth. Growth happening nicely on the revenue side. On the left-hand side, you can see the full year 24%. Clinical sector revenue grew by 68%. Actually, growth was accelerating in the second half of the year. That was a 45% increase compared to the previous year. And the clinical part was growing by 65%. And we actually got some non-clinical deals as well. So the non-clinical was in the second half staying more or less flat, but overall for FY 2025. So we are happy. So it was according to our plans, and of course, as I said. Now we are entering the scale-up phase. Revenue growth will definitely be in our focus. Strategy. This is the slide that I've been showing in previous announcements as well. The market is there. And it's absolutely gaining traction, especially last year and this year. Need is there. The amount of samples that you need to diagnose is growing. At the same time, the number of pathologists is staying the same or decreasing. And I can give you one example from our good customer from Italy. Large hospital region. They have 409 pathologists currently. They told us that in the next two years, 100 will retire, and only nine new people will come on board, meaning that they roughly lose 25% of their workforce in the next two years. And that was the reason why they are investing in digital pathology and AI because they want to be more productive and cover the gap that they will face in the coming years. And that was just one concrete example. But on the other hand, it's the same thing in all the countries. This lack of resources necessitates automation. So there is absolutely no question whether AI and this technology will move forward. And if we look at the process where we are. So we are talking about the laboratories where tissue samples are received, prepared, placed on glass slides, stained, digitized with a scanner, and then shared with pathologists for diagnosis. Our part is to support the diagnostic decision making. We show the image where the problems are. And then we also populate the report. We show the numbers as well. We do the quantitative analysis. And we cover, for example, the full test panel so that they can actually make the diagnostic decision based on that. And then it goes to a treatment. The interesting thing is that as the market is picking up, I would say that none of the other vendors on display are able to sell anything. Of course they sell something. But scanner, laboratory information system, and image management system sales are all linked to AI if they don't have an AI story. Where do you actually get a return on investment? So then it's not happening. That's why it's extremely easy now to make partnerships. And as I said before. So I think at some point in time there will be some consolidation happening as well because AI is driving the demand on this market. From our side. We are top of the curve on technology. We were the first company to pioneer deep learning-based AI back in 2015. Building that platform and then eventually the AI tools. Now we are using the Vision Transformers and the Foundation Engine, which is actually patent pending. And that links to different foundation models. But we are leading the pack on the technology side. And we can provide information for pathologists. What we provide is really accurate. And we can go much deeper than most of the competition. Then the business model is scalable, so that once adopted. We are talking about recurring revenues. And we haven't seen any churn with our customers. I'm sure that will be at some level in the future. But no local churn so far, and no revenue churn so far. So we are in an upselling mode at the moment. Then interoperability is a big thing, meaning that when you sell to a hospital or laboratory, you are not alone; you need to be able to support multiple surrounding systems. We have done that. So we are supporting all the major scanners, LIS systems, image management systems, and so on. So this is really a key. So that the whole business is not just building an algorithm. So it's really providing a solution which is robust and regulatory approved. And you can actually deploy and maintain. So, about the clinical suite. So we've been looking at the major areas where we built the offerings. I mentioned breast cancer, but there's also lung, colon, prostate, lymph node, and gastric cancer, and so on. So major organs. And we offer supporting solutions for those. Breast cancer is a good example from that perspective. So that when the pathologist is doing the diagnosis. So they need to do a so-called breast panel. And that panel contains six different areas. And you need to be diagnosing all of those. So, when you offer a solution for that area, it's good to have full coverage for all six because then you can automate everything. So if you have partial coverage, then you do some things automatically and some manually. But we are the only vendor who can actually provide the full panel for the end customers. And then think about the commercial point of view. Because when we sell. The idea is that you need to convince the user that we can do that. And then you need to convince IT that you can provide support and have all the connections to the surrounding systems. Then you have the budget owner. Who makes the decision? And then it comes back to the question where the ROI is coming from. And one thing is clear: You can do things much faster. You can do double or triple the amount of work in the same time. You can do it with a higher quality, less errors. So that's a big, big portion as well. And the other interesting thing was that now we have some data from a customer so that you can avoid ordering more expensive stainings. For example, in Paris with the prostate cancer. They were estimating that they needed to order every second case. They needed to order an IHC staining. Which is roughly about €50 per case. Now, when they started using AI for prostate cancer. So it's only 10% of the cases need that more expensive staining. The value proposition and return on investment is really coming from those angles. And then we go forward, of course. Then you can provide more prognostic insights and have more detailed data. So you can make better treatment decisions. And this is something that we haven't been talking about too much in these type of events. But at the end of the day. So the beneficiary here is the patient. Because you get a faster diagnosis, and first, you have the resources to do things. So you get your diagnosis quicker, can start the treatment, and the diagnosis itself is more accurate. So that we give more data than a human eye can actually do with the eyeballing of those samples. You can do much more precise treatment decisions. These are the expected benefits that we are providing. The other thing is, and this applies to the whole digital pathology and AI, so that if you have some remote locations where you don't have the best expert. In a digital and AI-driven world, you can get the same level of diagnosis in remote locations as well. So it provides more equal access to high-quality diagnosis and treatment. This is our current offering, and it is one of our longer-term ambitions to cover 80% of the typical clinical workflow. And that was one of the things that we said during the IPO four years ago, that this is what we are going to do, and we are actually moving really nicely forward on this process. We have a coverage of 60% currently, and it's likely that we will reach 80% by the end of the decade. The idea was that when you start automating those big workflows, it's good to provide enough solutions so that you don't need multiple different vendors for the IT department to manage, for example. And providing different user experiences and so on. Our strategy is that we have a full offering. We will be the leader in this industry. And that requires, of course, the best products in the market and the best coverage for clinical workflow. Last summer. We undertook a strategy refresh, without making major changes. But we were thinking about what the growth drivers are in the coming years. And for the very, very long term. I said, okay. We invested in ourselves, and it will deliver a nice amount of revenue for us, creating good opportunities, we believe, in the European area, including France. Italy. Spain. Nordic countries, UK. So there's a new market this year, by the way. We are opening up the DACH area as well, with many developments underway. So, there are developments in Italy. The driver was the Covid recovery fund, so most hospital regions moved forward with AI because they received the initial investment. They have roughly 15 hospital regions, and we have seven out of those. In France, the public sector is now heavily supporting the adaptation of AI. And as I said, we are the chosen one as AI vendor on that program. So we see that Europe will grow, and at the same time, we grow our offering. So more apps and a little bit of upstream and downstream expansion of our offering. And then, a fully integrated AI workflow. So that we will give more tools for pathologists to do their work. And then, the global opportunities there because it's a purely global market. Once we capture the opportunity in a key market, we can start expanding globally, and we already have nice customers outside of the core markets. But it means that then we start investing and capturing the opportunity at scale on those places. Then we have an approach for prognostic models. And some pharma companies have already approached us to develop a companion diagnostic solution together with them. Prognostic models we have already built with the Mayo Clinic. And there are significant expansion opportunities with current technology. Then business targets and objectives for the coming years. We are not giving out the financial forecast yet. But of course, internally, we have many ambitions for what we want to achieve. But the first one is to achieve financial independence by the end of 2027. So we changed the wording on this. So, it depends. So if we see that the market is really picking up, as it now seems. So then, we really focus on investing in capturing the market opportunity because we think that if you want to play the global leadership game, you need to be able to capture the opportunity fairly quickly. So then we keep our flexibility here. But it could mean that okay. If we continue and want to be profitable, then we focus on that. But we want to maintain that flexibility. This also has implications for financial independence. So, regarding financial independence, will an additional funding round be necessary? Those are the types of things. But that's what we are focusing on. I already mentioned the offering regarding the 50 accounts. Yes. So that's a really concrete plan. So now we have roughly 15 clinical customers on that bracket. And a very detailed plan how we are growing to 50 and more. So we are of course not stopping there. But that's the next step goal. And then of course, we have a nice technology that can be leveraged on multiple things. And we look those as opportunities. But now, yes. So I stop here. There's some room for questions.

Unknown 1
33:22 - 33:44

Okay, so let's take some questions from the chat. We have received some from Julius Natoma. Let's start by asking, can you talk about the scalability and revenue acceleration potential on the Foundation Engine as compared to convolutional neural networks?

Jukka Tapaninen
33:45 - 34:32

Well, the Foundation Engine we have is a technology that can link to multiple AI models. Currently, it speeds up the development cycle for us. And we acknowledge that. So, for market coverage and revenue. It is important that we have a wide portfolio and also tools that are generalizable, meaning that we can build. A solution that is easier to adapt to different types of staining. Different scanners, different kinds of surrounding systems. All in all. That's a core technology. But it will speed up the time to market from the development side.

Unknown 1
34:34 - 34:53

Thank you, Jukka. Next question is about AI. Healthcare budgets are largely driving the market. How do you see AI budget progressing in Europe? We know that budgets are strong in France and Italy. How do you see budget availability for your technology in the rest of Europe?

Jukka Tapaninen
34:54 - 36:14

Well, yeah. Italy and France are obviously driving that. But there are multiple other countries. When we talk with the public, it's different. Then we talk with the private sector. The private sector is more about the ROI story that we can provide. The public sector is waking up in multiple locations because they are undergoing a transformation. You have a certain way of doing things in hospitals and healthcare systems, and they need to change that. They have a budget in AI and digital pathology as well. That's happening. But then there are some accelerating things in some countries so that the public sector is stepping in, saying, 'Okay, you will get the funding for the next 1 or 2 years.' And that way you can start the project. Once you are in and you have done the transformation, it will continue. But there's a lot of things happening. And there's also a drive for European AI and all of those things. So we are actually in a good spot. If you think about the competition. There are not too many European companies in this field. Good progress on that side.

Unknown 1
36:14 - 36:25

Next question. Next question. Question is on cost base and personal expenses. Did H2 figures include some one-off costs related to streamlining the business?

Jukka Tapaninen
36:27 - 36:38

Yes. A short answer. And then also we did some leadership team recruitment. There were some extraordinary costs from those recruitment processes.

Unknown 1
36:40 - 36:50

Thank you. And then one final question. Could you tell more about the competition, specifically which companies offer similar AI products?

Jukka Tapaninen
36:52 - 38:03

I don't want to start promoting the competition too much, but there's one Israeli company who's focusing on a clinical side of the business typically, and so far in every single case. So we've been beating them in a competition when the customer starts comparing the products. But that's a good competitor. And then we have a couple of companies from the US and Germany, and Visiopharm from Denmark. But they are not exactly comparing apples to apples. So they miss some functionality, and we have something else. And sometimes we cooperate with those companies as well in a way on this business. But typically, the competition stops at a heatmap level, showing the image and the areas that might indicate problems. But in our case, we do the quantitative piece and provide the ready-made reports. So that differentiates us greatly, plus the breadth of the offering.

Unknown 1
38:04 - 38:16

And let's take one final question about the market sizes. What are the market sizes, especially in France, Italy, Spain and UK, based on the number of hospitals.

Jukka Tapaninen
38:18 - 39:01

That's a good question, so I cannot give an exact answer. So we've been doing, of course, a business planning exercise where we categorize the hospitals into large, medium, and small that align with our ideal customer profile. But we are talking about thousands of opportunities and what I can say from our pipeline. So currently we had as of Monday when we last checked. We had over 200 line items in a pipeline. So there is a demand. So they are of course not all clinical cases, but it indicates that there is significant interest and no limitation. So, there is no limitation on the number of hospitals or clinics, nor on the extent of the need.

Unknown 1
39:02 - 39:05

Thank you Jukka. Those were all the questions for today.

Jukka Tapaninen
39:05 - 39:31

All right. Thank you so much. And at the end. I just wanted to highlight the next events. So we are going to release. The report will be released next week. On the 11th. Then we have the Annual General Meeting on April 2nd. And the next financial report is released on August 28th. But thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…